Founded in 1995, Lawley Pharmaceuticals is a privately owned, Perth-based Australian company and a global leader in the research and development of transdermal testosterone therapies for both women and men.
In 2020, over two decades of dedication culminated in Australian regulatory approvals that marked global breakthroughs in testosterone treatment.
AndroFeme® 1 is the world’s first female testosterone cream to receive global licensing—pioneering treatment for hypoactive sexual desire dysfunction in postmenopausal women.
For men, AndroForte® 5 offers a low-dose, fast-absorbing, and cost-effective testosterone option via scrotal application. This method enhances safety by reducing third-party passive transfer and significantly lowers treatment costs for patients and healthcare systems.
At Lawley, we believe in working with the body—not against it—by delivering testosterone hormone therapies that are body-identical, effective, and trusted.
Available nationally in Australia and under Section 29 in New Zealand.
